
Benjamin Glicksberg, PhD
About Me
Benjamin Glicksberg, Ph.D. is an Associate Professor in the Windreich Department of Artificial Intelligence and Human Health and the Founding Director of the Center for AI in Children’s Health at the Icahn School of Medicine. He is also a Member of the Mindich Child Health and Development Institute, the Hasso Plattner Institute for Digital Health, and Adjunct Faculty of Digital Engineering at the Hasso Planner Institute in Potsdam, Germany. Formerly, he served on the leadership team as the VP and Head of Data Science and Machine Learning of Character Biosciences, a precision health drug development company using genomics to develop novel therapeutics for progressive diseases of aging. Prior to Character Biosciences, Dr. Glicksberg was an Assistant Professor in Genetics and Genomic Sciences at the Icahn School of Medicine at Mount Sinai. His research broadly uses machine learning on multi-modal and multi-omic patient data for personalizing medicine. His work often involves the analysis and integration of diverse multi-modal and multi-omic biomedical data, such as Electronic Health Records (EHR), clinical text, genomics, physiological waveforms, videos, and images, for applications ranging from predictive modeling to drug discovery. Dr. Glicksberg received his Ph.D. from the Icahn School of Medicine at Mount Sinai and completed post-doctoral work at the University of California, San Francisco.
Language
English
Position
ASSOCIATE PROFESSOR | Artificial Intelligence and Human Health
Research Topics
Bioinformatics, Biomedical Informatics, Biomedical Sciences, Biostatistics, Computational Biology, Computer Simulation, Genetics, Genomics, Healthcare, Imaging, Pediatrics, Personalized Medicine
Multi-Disciplinary Training Areas
Artificial Intelligence and Emerging Technologies in Medicine [AIET]
Education
PhD, Icahn School of Medicine at Mount Sinai
Post-doctoral, University of Califnornia, San Francisco
Publications
Selected Publications
- Orchestrated multi agents sustain accuracy under clinical-scale workloads compared to a single agent. Eyal Klang, Mahmud Omar, Ganesh Raut, Reem Agbareia, Prem Timsina, Robert Freeman, Nicholas Gavin, Lisa Stump, Alexander W. Charney, Benjamin S. Glicksberg, Girish N. Nadkarni. npj Health Systems
- Development and multicentre validation of an artificial intelligence electrocardiogram model for ventricular remodeling in repaired tetralogy of Fallot. Son Q. Duong, Akhil Vaid, Pengfei Jiang, Yuval Bitterman, Yamini Krishnamurthy, I. Min Chiu, Joshua Finer, Brian Cleary, Benjamin S. Glicksberg, Ruchira Garg, Michael DiLorenzo, Mark Friedberg, Evan Zahn, Matthew Lewis, Michael Satzer, David Ouyang, Pierre Elias, Tal Geva, Sunil Ghelani, Brett R. Anderson, Ali Zaidi, Rachel M. Wald, Girish N. Nadkarni, Joshua Mayourian. European Heart Journal - Digital Health
- The role of artificial intelligence in cardio-obstetrics – current applications and future directions. Gurleen Wander, Thomas M. Hopkins, Andrew Scatola, Guthrie Ruby, Mark R. Johnson, Shilpi Mehta-Lee, Benjamin S. Glicksberg, Chayakrit Krittanawong. Trends in Cardiovascular Medicine
Industry Relationships
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device, biotechnology companies, and other outside entities to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their outside financial relationships.
Below are financial relationships with industry reported by Dr. Glicksberg during 2025 and/or 2026. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Consulting or Other Professional Services Examples include, but are not limited to, committee participation, data safety monitoring board (DSMB) membership
- Lucem Health
- Scale Medicine
- Triveni Bio
- ArtemisAI Labs
- Violet Research Institute
- Heartsciences
- Lymeless, Inc.
- Phylo
- Character Biosciences
Equity (Stock or stock options valued at greater than 5% ownership of a publicly traded company or equity of any value in a privately held company)
- ArtemisAI Labs
- Phylo
- Character Biosciences
Founder/Co-Founder/Partner
- ArtemisAI Labs
Mount Sinai’s faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.